{
    "nct_id": "NCT05668988",
    "official_title": "A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation",
    "inclusion_criteria": "1. Aged at least 18 years old (or per local regulatory/IRB requirement).\n2. Histologically or cytologically confirmed diagnosis of non-squamous NSCLC, locally advanced (Stage IIIB and IIIC according to the 8th edition of the AJCC TNM staging criteria) or metastatic (Stage IV), not suitable for curative therapy.\n3. Adequate tumor tissue available, for central laboratory confirmation of EGFR exon 20 insertion mutation\n4. At least 1 measurable lesion per RECIST Version 1.1\n5. Life expectancy â‰¥ 12 weeks\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n7. Adequate organ and hematologic function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Prior treatment with any systemic anti-cancer therapy for locally advanced or metastatic NSCLC.\n2. Spinal cord compression or leptomeningeal metastasis.\n3. Concurrent EGFR mutations: exon 19 deletion, L858R, T790M, G719X, S768I, or L861Q.\n4. History of stroke or intracranial hemorrhage within 6 months before randomization.\n5. As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses (i.e., hemophilia and Von Willebrand disease).",
    "miscellaneous_criteria": ""
}